A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

by | Jan 6, 2026 | Clinical Trials | 0 comments

​ Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions: Biological: BCD-281; Biological: Ocrelizumab

Sponsors: Biocad

Recruiting Conditions: Relapsing-remitting Multiple Sclerosis (RRMS)
Interventions: Biological: BCD-281; Biological: Ocrelizumab
Sponsors: Biocad
Recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *